Praxis Precision Medicines
PRAX
134 hedge funds and large institutions have $1.09B invested in Praxis Precision Medicines in 2024 Q3 according to their latest regulatory filings, with 34 funds opening new positions, 44 increasing their positions, 45 reducing their positions, and 13 closing their positions.
162% more first-time investments, than exits
New positions opened: 34 | Existing positions closed: 13
43% more capital invested
Capital invested by funds: $762M → $1.09B (+$329M)
20% more call options, than puts
Call options by funds: $24M | Put options by funds: $20M
19% more funds holding
Funds holding: 113 → 134 (+21)
0% more funds holding in top 10
Funds holding in top 10: 5 → 5 (0)
2% less repeat investments, than reductions
Existing positions increased: 44 | Existing positions reduced: 45
1.44% less ownership
Funds ownership: 107.68% → 106.24% (-1.4%)
Top Buyers
| 1 |
Capital Research Global Investors
Los Angeles,
California
|
+$53.9M |
| 2 |
PA
Perceptive Advisors
New York
|
+$22.4M |
| 3 |
Franklin Resources
San Mateo,
California
|
+$11.1M |
| 4 |
BBA
Baker Bros. Advisors
New York
|
+$10.3M |
| 5 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$9.99M |
Top Sellers
PRAX Hedge Fund Activity: Q3 2024 in Review
134 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Praxis Precision Medicines (PRAX) for Q3 2024, worth a combined $1.09B — up 43% from $762M a quarter earlier.
Buyers outnumbered sellers: 34 funds opened new PRAX positions and 13 closed out — a net gain of 21 holders — while 44 added to existing stakes and 45 trimmed.
The largest buyer was Capital Research Global Investors, opening a new position worth an estimated $53.9M. The largest seller was RA Capital Management, cutting an estimated $25.6M.
- 134 institutional investors held Praxis Precision Medicines (PRAX) as of Q3 2024, up from 113 in Q2 2024.
- Funds reported $1.09B of Praxis Precision Medicines stock for Q3 2024, up 43% quarter-over-quarter.
- 34 funds opened new Praxis Precision Medicines positions in Q3 2024 and 13 closed out, a net change of +21 holders.
- The largest Praxis Precision Medicines buyer in Q3 2024 was Capital Research Global Investors, an estimated $53.9M added.
- The largest Praxis Precision Medicines seller in Q3 2024 was RA Capital Management, an estimated $25.6M sold.
Based on aggregated 13F filings for Q3 2024.